Literature DB >> 29757136

On the cost-utility of methylene blue-photoinactivated plasma versus quarantine plasma in Spain.

Arturo Pereira1, Julio Del Río-Garma2, José A García-Erce3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29757136      PMCID： PMC6343590          DOI： 10.2450/2018.0056-18

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  4 in total

Review 1.  Will pathogen reduction of blood components harm more people than it helps in developed countries?

Authors:  John R Hess; Monica B Pagano; James D Barbeau; Pär I Johannson
Journal:  Transfusion       Date:  2016-05       Impact factor: 3.157

2.  Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma.

Authors:  Joseph B Babigumira; Solomon J Lubinga; Emma Castro; Brian Custer
Journal:  Blood Transfus       Date:  2016-11-16       Impact factor: 3.443

3.  Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate.

Authors:  R Atance; A Pereira; B Ramírez
Journal:  Transfusion       Date:  2001-12       Impact factor: 3.157

4.  Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study.

Authors:  Julio del Río-Garma; Alberto Alvarez-Larrán; Clara Martínez; Josep Muncunill; Dolors Castellà; Javier de la Rubia; Concepción Zamora; Mercedes Corral; Aurora Viejo; Francisco Peña; Pilar Rodríguez-Vicente; Enric Contreras; Cristina Arbona; Consuelo Ramírez; José A Garcia-Erce; Adrián Alegre; José Mateo; Arturo Pereira
Journal:  Br J Haematol       Date:  2008-07-14       Impact factor: 6.998
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.